ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Janssen’s myeloma CAR T therapy cilta-cel demonstrates ‘sustained efficacy’
June 03, 2021Janssen has reported new data for its B-cell maturation antigen (BCMA) directed CAR T therapy ciltacabtagene autoleucel (cilta-cel) in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. -
Janssen's CAR-T shows 100% response rate in multiple myeloma
May 14, 2020Janssen has unveiled updated results from a mid-stage trial of its CAR-T therapy JNJ-4528, showing high rates of response in patients with relapsed or refractory multiple myeloma.
Pharma Sources Insight January 2025
